Suppr超能文献

相似文献

1
Potent and specific peptide inhibitors of human pro-survival protein Bcl-xL.
J Mol Biol. 2015 Mar 27;427(6 Pt B):1241-1253. doi: 10.1016/j.jmb.2014.09.030. Epub 2014 Nov 14.
2
Determinants of BH3 binding specificity for Mcl-1 versus Bcl-xL.
J Mol Biol. 2010 May 21;398(5):747-62. doi: 10.1016/j.jmb.2010.03.058. Epub 2010 Apr 2.
6
By any means necessary: discovering a Bcl-xL specific domain.
J Mol Biol. 2015 Mar 27;427(6 Pt B):1239-1240. doi: 10.1016/j.jmb.2014.12.016. Epub 2014 Dec 31.
8
Minimal BH3 peptides promote cell death by antagonizing anti-apoptotic proteins.
J Biol Chem. 2003 May 23;278(21):19426-35. doi: 10.1074/jbc.M209472200. Epub 2003 Mar 17.
9
Chelerythrine and sanguinarine dock at distinct sites on BclXL that are not the classic BH3 binding cleft.
J Mol Biol. 2006 Dec 1;364(3):536-49. doi: 10.1016/j.jmb.2006.09.023. Epub 2006 Sep 14.
10
Locating Herpesvirus Bcl-2 Homologs in the Specificity Landscape of Anti-Apoptotic Bcl-2 Proteins.
J Mol Biol. 2015 Jul 31;427(15):2468-2490. doi: 10.1016/j.jmb.2015.05.015. Epub 2015 May 23.

引用本文的文献

1
Computational design of potent and selective binders of BAK and BAX.
Sci Adv. 2025 Sep 5;11(36):eadt4170. doi: 10.1126/sciadv.adt4170.
3
Protein-Based Degraders: From Chemical Biology Tools to Neo-Therapeutics.
Chem Rev. 2025 Feb 26;125(4):2120-2183. doi: 10.1021/acs.chemrev.4c00595. Epub 2025 Jan 17.
5
Modeling the Binding of Anticancer Peptides and Mcl-1.
Int J Mol Sci. 2024 Jun 13;25(12):6529. doi: 10.3390/ijms25126529.
6
Machine learning to predict continuous protein properties from binary cell sorting data and map unseen sequence space.
Proc Natl Acad Sci U S A. 2024 Mar 12;121(11):e2311726121. doi: 10.1073/pnas.2311726121. Epub 2024 Mar 7.
7
Design of Protein Segments and Peptides for Binding to Protein Targets.
Biodes Res. 2022 Apr 15;2022:9783197. doi: 10.34133/2022/9783197. eCollection 2022.
9
Rational design of Harakiri (HRK)-derived constrained peptides as BCL-x inhibitors.
Chem Commun (Camb). 2023 Feb 7;59(12):1697-1700. doi: 10.1039/d2cc06029a.

本文引用的文献

1
Stapled α-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy.
Proc Natl Acad Sci U S A. 2013 Sep 3;110(36):E3445-54. doi: 10.1073/pnas.1303002110. Epub 2013 Aug 14.
2
A comparison of two strategies for affinity maturation of a BH3 peptide toward pro-survival Bcl-2 proteins.
ACS Synth Biol. 2012 Mar 16;1(3):89-98. doi: 10.1021/sb200002m. Epub 2011 Oct 7.
3
BH3 profiling in whole cells by fluorimeter or FACS.
Methods. 2013 Jun 1;61(2):156-64. doi: 10.1016/j.ymeth.2013.04.006. Epub 2013 Apr 20.
4
Structure-guided design of a selective BCL-X(L) inhibitor.
Nat Chem Biol. 2013 Jun;9(6):390-7. doi: 10.1038/nchembio.1246. Epub 2013 Apr 21.
5
Direct activation of full-length proapoptotic BAK.
Proc Natl Acad Sci U S A. 2013 Mar 12;110(11):E986-95. doi: 10.1073/pnas.1214313110. Epub 2013 Feb 12.
6
Peptide ligands for pro-survival protein Bfl-1 from computationally guided library screening.
ACS Chem Biol. 2013 Apr 19;8(4):778-88. doi: 10.1021/cb300679a. Epub 2013 Feb 21.
7
Predictive Bcl-2 family binding models rooted in experiment or structure.
J Mol Biol. 2012 Sep 7;422(1):124-44. doi: 10.1016/j.jmb.2012.05.022. Epub 2012 May 19.
8
BH3 profiling--measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions.
Cancer Lett. 2013 May 28;332(2):202-5. doi: 10.1016/j.canlet.2011.12.021. Epub 2012 Jan 8.
9
Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy.
Science. 2011 Nov 25;334(6059):1129-33. doi: 10.1126/science.1206727. Epub 2011 Oct 27.
10
Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases.
EMBO J. 2011 Aug 23;30(18):3667-83. doi: 10.1038/emboj.2011.307.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验